Advertisement
Screener

CYPHERPUNK TECHNOLOGIES INC. (CYPH) Investment Income, Nonoperating

1.6 / 5 stars · 20/63 Roast Me

CYPHERPUNK TECHNOLOGIES INC. Investment Income, Nonoperating

CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Investment Income, Nonoperating of $63.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Income Statement › Other Income

us-gaap:InvestmentIncomeNonoperating · last filed 2026-08-12

  • CYPHERPUNK TECHNOLOGIES INC. investment income, nonoperating for the quarter ending 2026-06-30 was $63.00K, a 74.39% decline year-over-year.
  • CYPHERPUNK TECHNOLOGIES INC. investment income, nonoperating for the quarter ending 2026-03-31 was $95.00K, a 78.26% decline year-over-year.
  • CYPHERPUNK TECHNOLOGIES INC. investment income, nonoperating for the quarter ending 2025-12-31 was $110.00K, a 81.51% decline year-over-year.
  • CYPHERPUNK TECHNOLOGIES INC. investment income, nonoperating for the quarter ending 2025-09-30 was $123.00K, a 86.24% decline year-over-year.
  • CYPHERPUNK TECHNOLOGIES INC. investment income, nonoperating for fiscal 2025 was $916.00K, a 70.73% decline from fiscal 2024.
  • CYPHERPUNK TECHNOLOGIES INC. investment income, nonoperating for fiscal 2024 was $3.13M.
Period endInvestment Income, Nonoperating 3 monthInvestment Income, Nonoperating 6 monthInvestment Income, Nonoperating 9 monthInvestment Income, Nonoperating 12 month
2026-06-30$63.00K
10-Q · filed 2026-08-12
$158.00K
10-Q · filed 2026-08-12
$268.00K
derived: sum of 3 quarters · filed 2026-08-12
$391.00K
derived: sum of 4 quarters · filed 2026-08-12
2026-03-31$95.00K
10-Q · filed 2026-05-14
$205.00K
derived: sum of 2 quarters · filed 2026-05-14
$328.00K
derived: sum of 3 quarters · filed 2026-05-14
$574.00K
derived: sum of 4 quarters · filed 2026-08-12
2025-12-31$110.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16
$233.00K
derived: sum of 2 quarters · filed 2026-03-16
$479.00K
derived: sum of 3 quarters · filed 2026-08-12
$916.00K
10-K · filed 2026-03-16
2025-09-30$123.00K
10-Q · filed 2025-11-12
$369.00K
derived: sum of 2 quarters · filed 2026-08-12
$806.00K
10-Q · filed 2025-11-12
$1.40M
derived: sum of 4 quarters · filed 2026-08-12
2025-06-30$246.00K
10-Q · filed 2026-08-12
$683.00K
10-Q · filed 2026-08-12
$1.28M
derived: sum of 3 quarters · filed 2026-08-12
$2.17M
derived: sum of 4 quarters · filed 2026-08-12
2025-03-31$437.00K
10-Q · filed 2026-05-14
$1.03M
derived: sum of 2 quarters · filed 2026-05-14
$1.93M
derived: sum of 3 quarters · filed 2026-05-14
$2.79M
derived: sum of 4 quarters · filed 2026-05-14
2024-12-31$595.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16
$1.49M
derived: sum of 2 quarters · filed 2026-03-16
$2.35M
derived: sum of 3 quarters · filed 2026-03-16
$3.13M
10-K · filed 2026-03-16
2024-09-30$894.00K
10-Q · filed 2025-11-12
$1.76M
derived: sum of 2 quarters · filed 2025-11-12
$2.53M
10-Q · filed 2025-11-12
2024-06-30$865.00K
10-Q · filed 2025-08-14
$1.64M
10-Q · filed 2025-08-14
2024-03-31$775.00K
10-Q · filed 2025-05-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
Quoin Pharmaceuticals Ltd. (QNRX)$0.443B-17.85
PROTHENA CORP PUBLIC LTD CO (PRTA)Ireland$0.428B-11.53
DiaMedica Therapeutics Inc. (DMAC)United States$0.423B-10.11
MapLight Therapeutics, Inc. (MPLT)United States$0.459B-7.10
Atea Pharmaceuticals, Inc. (AVIR)United States$0.414B-2.26
ARS Pharmaceuticals, Inc. (SPRY)United States$0.414B-3.70
RELMADA THERAPEUTICS, INC. (RLMD)United States$0.406B-11.92
Opus Genetics, Inc. (IRD)United States$0.406B-3.16
Arcturus Therapeutics Holdings Inc. (ARCT)$0.402B-2.05
GALECTIN THERAPEUTICS INC (GALT)United States$0.399B-11.06